PRESS RELEASE published on 08/16/2023 at 07:00, 1 year 3 months ago Biophytis announces next regulatory steps in Europe and the United States for its COVA project
PRESS RELEASE published on 08/08/2023 at 07:00, 1 year 3 months ago Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe
PRESS RELEASE published on 07/20/2023 at 07:00, 1 year 4 months ago Biophytis: Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19
PRESS RELEASE published on 07/19/2023 at 07:53, 1 year 4 months ago Biophytis Announces $3.8 Million Registered Direct Offering
PRESS RELEASE published on 07/18/2023 at 07:00, 1 year 4 months ago Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound
PRESS RELEASE published on 07/10/2023 at 07:00, 1 year 4 months ago Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia
PRESS RELEASE published on 06/19/2023 at 07:00, 1 year 5 months ago Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress
PRESS RELEASE published on 06/16/2023 at 23:00, 1 year 5 months ago Biophytis: RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED
PRESS RELEASE published on 06/05/2023 at 08:00, 1 year 5 months ago Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June
PRESS RELEASE published on 05/26/2023 at 08:00, 1 year 5 months ago Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-1
Published on 11/22/2024 at 00:00, 7 hours 33 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 9 hours 28 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 9 hours 43 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 11 hours 18 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 11 hours 23 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/22/2024 at 07:23, 10 minutes ago EQS-Adhoc: Entering into agreements for the acquisition of a majority stake in OTRS AG by Optimus BidCo AG, an acquisition company of Easyvista SAS, for a purchase price of EUR 17 per share
Published on 11/22/2024 at 07:00, 33 minutes ago Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024
Published on 11/22/2024 at 07:00, 33 minutes ago SoftwareOne completes its CHF 70 million share buyback programme
Published on 11/22/2024 at 07:00, 33 minutes ago beaconsmind AG: First Berlin increases price target to EUR 18.50 and continues to rate share as “Buy”
Published on 11/22/2024 at 06:45, 48 minutes ago The Komax Group is making good progress in the implementation of its strategy
Published on 11/21/2024 at 06:58, 1 day ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 12 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 13 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 13 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 23 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
